Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
82 hedge funds and large institutions have $234M invested in Mersana Therapeutics in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 10 closing their positions.
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more funds holding
Funds holding: 69 → 82 (+13)
15% more capital invested
Capital invested by funds: $203M → $234M (+$30.7M)
0.57% more ownership
Funds ownership: 2.96% → 3.53% (+0.57%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $58K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$8.39M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$8.33M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$5.78M |
| 4 |
BlackRock
New York
|
+$5.74M |
| 5 |
Axa
Paris,
France
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.08M |
| 2 |
Millennium Management
New York
|
-$2.03M |
| 3 |
JP Morgan Chase
New York
|
-$1.62M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.16M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$943K |
MRSN Hedge Fund Activity: Q1 2020 in Review
82 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2020, worth a combined $234M — up 15% from $203M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MRSN positions and 10 closed out — a net gain of 16 holders — while 33 added to existing stakes and 13 trimmed.
The largest buyer was Ghost Tree Capital, adding an estimated $8.39M. The largest seller was OrbiMed, cutting an estimated $5.08M.
- 82 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2020, up from 69 in Q4 2019.
- Funds reported $234M of Mersana Therapeutics stock for Q1 2020, up 15% quarter-over-quarter.
- 26 funds opened new Mersana Therapeutics positions in Q1 2020 and 10 closed out, a net change of +16 holders.
- The largest Mersana Therapeutics buyer in Q1 2020 was Ghost Tree Capital, an estimated $8.39M added.
- The largest Mersana Therapeutics seller in Q1 2020 was OrbiMed, an estimated $5.08M sold.
Based on aggregated 13F filings for Q1 2020.